ASND Ascendis: Price-to-Projected Revenue Ratio

Ascendis Pharma A/S - graphic logo of issuer ASND

The forward P/S multiple trend confirms the authority of Ascendis Pharma A/S (ASND) in treating endocrine pathologies. Growth is supported by the implementation of extended-release injections for patient comfort and strict adherence to Danish economic standards in laboratories. The value of 17.70 represents the current metric, capturing market expectations for the company's capitalization relative to projected future sales volumes.

Ascendis Pharma - ASND Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for Ascendis (ASND)

- market price and analyst price targets:
Price Chart Ascendis Pharma|ASND - Average Forecast Price
- company stock capitalization data:
Market Value Ascendis|ASND - Total Company Value
- book value of equity indicators:
Book Value per Share Ascendis Pharma|ASND - Book Valuation of Business|Market Value to Book Value Ratio ascendispharma.com|ASND - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Ascendis Pharma A/S|ASND - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ascendis Pharma A/S|ASND - Company Aggregate Debts|Debt to Book Capitalization Ratio Ascendis|ASND - Long-Term Debt Volume|Company Short-Term Debts Ascendis Pharma|Quick Ratio ascendispharma.com
- financial results and valuation multiples details:
ASND - Company Net Income|Expected Profit Ascendis Pharma A/S|ASND - Price to Earnings Multiple|Forward P/E Multiple Ascendis Pharma Inc.|ASND - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Ascendis|ASND - Operating income before deduction of amortization|Earnings per share for the last twelve months Ascendis Pharma|ASND - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months ascendispharma.com|ASND - Earnings per share increase in current year|Net earnings per share growth forecast for next year Ascendis Pharma A/S
- sales volume and revenue indicators:
ASND - Company Annual Revenue|Projected Sales Volume Ascendis Pharma|ASND - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Ascendis
Fundamental company analysis:ASND (Ascendis Pharma)
Original product of Ascendis

The forward P/S ratio compares the current market value of the company with expected sales volume, determining the premium investors are willing to pay for future growth. Analyzing the forward P/S of the business allows for the filtering out of short-term volatility, revealing real demand for shares through price action. For Ascendis Pharma A/S (ASND), this indicator reflects the market's confidence in the commercial success of the breakthrough TransCon technology and the scientific foundation of the Danish biopharma.

Analysis of competing companies

Price-to-Projected Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Market Cap to Future Revenue Ratio|RYTM - Price-to-Projected Revenue Ratio|AKRO: Price-to-Projected Revenue Ratio|MTSR: Forward P/S Multiple|MLTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Soleno (SLNO)|Forward Price-to-Revenue Multiple Amicus Corp FOLD|Forward P/S Multiple ETNB (89bio, Inc.)|Forward P/S Multiple agios.com AGIO|GPCR - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio MiMedx Group Inc MDXG|RZLT: Forward P/S Multiple|Forward Price-to-Revenue Multiple Lexicon Corp|MBX (MBX Biosciences Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio altimmune.com ALT|Price-to-Projected Revenue Ratio Aardvark Therapeutics (AARD)|Sagimet Biosciences, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple BIOA (BioAge Labs Inc.)|BMEA: Market Cap to Projected Revenue|Quince - Forward P/S Multiple|Market Cap to Expected Sales Ratio fractyl.com GUTS|vtvtherapeutics.com (VTVT) - Price-to-Projected Revenue Ratio|ATPC - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PLUR|SYBX: Forward Price to Sales|Price-to-Projected Revenue Ratio Lipocine Inc. (LPCN)|MTNB: Future Price to Revenue|Forward P/S Multiple SPRB (Spruce Biosciences, Inc.)|Forward Price to Sales GLTO|Carmell Corp - Forward P/S Multiple|LUMO - Forward P/S Multiple|Organovo Holdings, Inc. (ONVO) - Price-to-Projected Revenue Ratio|radiuspharm.com - Forward Price to Sales